Mark L Levitt

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Venues

Cancers

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Faizal Z Asumda, Nellie A Campbell, Mohamed A Hassan, Reza Fathi, Daniella F Vasquez Rico, Melanie Kiem, Ethan V Vang, Yo Han Kim, Xin Luo, Daniel R O'Brien, Sarah A Buhrow, Joel M Reid, Michael J Moore, Vered Katz Ben-Yair, Mark L Levitt, Jennifer L Leiting, Amro M Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J Truty, Lewis Rowland Roberts
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. Cancers 16 (5) (2024)
Faizal Z Asumda, Nellie A Campbell, Mohamed A Hassan, Reza Fathi, Daniella F Vasquez Rico, Melanie Kiem, Ethan V Vang, Yo Han Kim, Xin Luo, Daniel R O'Brien, Sarah A Buhrow, Joel M Reid, Michael J Moore, Vered Katz Ben-Yair, Mark L Levitt, Jennifer L Leiting, Amro M Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J Truty, Lewis Rowland Roberts
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. Cancers 16 (5) (2024)
Faizal Z Asumda, Nellie A Campbell, Mohamed A Hassan, Reza Fathi, Daniella F Vasquez Rico, Melanie Kiem, Ethan V Vang, Yo Han Kim, Xin Luo, Daniel R O'Brien, Sarah A Buhrow, Joel M Reid, Michael J Moore, Vered Katz Ben-Yair, Mark L Levitt, Jennifer L Leiting, Amro M Abdelrahman, Xinli Zhu, Fabrice Lucien, Mark J Truty, Lewis Rowland Roberts
Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts. Cancers 16 (5) (2024)
Charles D Smith, Lynn W Maines, Staci N Keller, Vered Katz Ben-Yair, Reza Fathi, Terry F Plasse, Mark L Levitt
Recent Progress in the Development of Opaganib for the Treatment of Covid-19. Drug design, development and therapy 16 (2022)

Mark L Levitt.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mark L Levitt